Hologic, Inc. (HOLX) Rating Reiterated by Stifel Nicolaus
Hologic, Inc. (NASDAQ:HOLX)‘s stock had its “buy” rating restated by stock analysts at Stifel Nicolaus in a research note issued on Friday.
A number of other research analysts have also commented on HOLX. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, March 29th. Leerink Swann reiterated an “outperform” rating and issued a $52.00 price target on shares of Hologic in a research note on Thursday, March 30th. Needham & Company LLC upped their price target on shares of Hologic from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, April 4th. Barclays PLC set a $50.00 price target on shares of Hologic and gave the company a “buy” rating in a research note on Wednesday, April 5th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $53.00 price target on shares of Hologic in a research note on Tuesday, May 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the stock. Hologic presently has an average rating of “Buy” and an average target price of $47.77.
Shares of Hologic (HOLX) opened at 44.61 on Friday. The firm has a market capitalization of $12.49 billion, a P/E ratio of 15.99 and a beta of 0.91. Hologic has a 12 month low of $35.15 and a 12 month high of $46.80. The stock has a 50 day moving average price of $44.35 and a 200 day moving average price of $42.22.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.46 by $0.04. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The business had revenue of $715.40 million for the quarter, compared to analyst estimates of $685.24 million. During the same quarter in the prior year, the business earned $0.47 EPS. Hologic’s quarterly revenue was up 3.2% on a year-over-year basis. On average, analysts expect that Hologic will post $2.01 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Hologic, Inc. (HOLX) Rating Reiterated by Stifel Nicolaus” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/hologic-inc-holx-rating-reiterated-by-stifel-nicolaus/1447930.html.
In related news, Director Sally Crawford sold 16,969 shares of the stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $44.00, for a total value of $746,636.00. Following the completion of the transaction, the director now owns 157,305 shares of the company’s stock, valued at approximately $6,921,420. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lawrence M. Levy sold 10,836 shares of the stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $42.49, for a total transaction of $460,421.64. Following the completion of the transaction, the director now directly owns 25,839 shares of the company’s stock, valued at approximately $1,097,899.11. The disclosure for this sale can be found here. In the last three months, insiders sold 107,240 shares of company stock valued at $4,716,859. 0.79% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in HOLX. Lincoln Capital Corp acquired a new position in Hologic during the fourth quarter valued at about $377,000. UBS Asset Management Americas Inc. increased its position in Hologic by 123.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,446,445 shares of the medical equipment provider’s stock valued at $58,032,000 after buying an additional 798,541 shares during the last quarter. Whalerock Point Partners LLC increased its position in Hologic by 57.4% in the fourth quarter. Whalerock Point Partners LLC now owns 37,850 shares of the medical equipment provider’s stock valued at $1,519,000 after buying an additional 13,800 shares during the last quarter. Teachers Advisors LLC increased its position in Hologic by 28.8% in the fourth quarter. Teachers Advisors LLC now owns 643,547 shares of the medical equipment provider’s stock valued at $25,819,000 after buying an additional 143,960 shares during the last quarter. Finally, Kentucky Retirement Systems acquired a new position in Hologic during the fourth quarter valued at about $810,000. 94.04% of the stock is owned by hedge funds and other institutional investors.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.